Photo of Michael Goldberg,  PhD

Michael Goldberg, PhD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 909-8181
Fax: (617) 582-9610


michael_goldberg1@dfci.harvard.edu

Michael Goldberg, PhD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Assistant Professor, Microbiology and Immunobiology, Harvard Medical School
  • Assistant Professor, Cancer Immunology & Virology, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Research Abstract

The Goldberg Lab strives to develop and deliver novel therapeutics in order to improve the lives of patients. We combine the tools of synthetic chemistry, molecular biology, materials science, bioengineering, and immunology to address important problems that are intractable from a uni-disciplinary approach. Our single-minded goal is to contribute to the betterment of human health – particularly in the realm of cancer – and we believe that this mission is best accomplished in the friendly, exciting, and stimulating environment offered here at the Dana-Farber Cancer Institute.

Publications

Powered by Harvard Catalyst
  • Wang L, Amoozgar Z, Huang J, Saleh MH, Xing D, Orsulic S, Goldberg MS. Decitabine enhances lymphocyte migration and function and synergizes with CTLA-4 blockade in a murine ovarian cancer model. Cancer Immunol Res 2015. PubMed
  • Goldberg MS. Immunoengineering: how nanotechnology can enhance cancer immunotherapy. Cell 2015; 161:201-4. PubMed
  • Amoozgar Z, Wang L, Brandstoetter T, Wallis SS, Wilson EM, Goldberg MS. Dual-Layer Surface Coating of PLGA-Based Nanoparticles Provides Slow-Release Drug Delivery To Achieve Metronomic Therapy in a Paclitaxel-Resistant Murine Ovarian Cancer Model. Biomacromolecules 2014. PubMed
  • Bell RE, Khaled M, Netanely D, Schubert S, Golan T, Buxbaum A, Janas MM, Postolsky B, Goldberg MS, Shamir R, Levy C. Transcription factor/microRNA axis blocks melanoma invasion program by miR-211 targeting NUAK1. J Invest Dermatol 2014; 134:441-51. PubMed
  • Brock A, Krause S, Li H, Kowalski M, Goldberg MS, Collins JJ, Ingber DE. Silencing HoxA1 by intraductal injection of siRNA lipidoid nanoparticles prevents mammary tumor progression in mice. Sci Transl Med 2014; 6:217ra2. PubMed
  • Goldberg MS. siRNA Delivery for the treatment of ovarian cancer. Methods 2013. PubMed
  • Goldberg MS, Hook SS, Wang AZ, Bulte JW, Patri AK, Uckun FM, Cryns VL, Hanes J, Akin D, Hall JB, Gharkholo N, Mumper RJ. Biotargeted nanomedicines for cancer: six tenets before you begin. Nanomed 2013; 8:299-308. PubMed
  • Goldberg MS, Sharp PA. Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression. J Exp Med 2012; 209:217-24. PubMed
  • Goldberg MS, Xing D, Ren Y, Orsulic S, Bhatia SN, Sharp PA. Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells. Proc Natl Acad Sci U S A 2011; 108:745-50. PubMed
  • Akinc A, Zumbuehl A, Goldberg M, Leshchiner ES, Busini V, Hossain N, Bacallado SA, Nguyen DN, Fuller J, Alvarez R, Borodovsky A, Borland T, Constien R, de Fougerolles A, Dorkin JR, Narayanannair Jayaprakash K, Jayaraman M, John M, Koteliansky V, Manoharan M, Nechev L, Qin J, Racie T, Raitcheva D, Rajeev KG, Sah DW, Soutschek J, Toudjarska I, Vornlocher HP, Zimmermann TS, Langer R, Anderson DG. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 2008; 26:561-9. PubMed
  • John M, Constien R, Akinc A, Goldberg M, Moon YA, Spranger M, Hadwiger P, Soutschek J, Vornlocher HP, Manoharan M, Stoffel M, Langer R, Anderson DG, Horton JD, Koteliansky V, Bumcrot D. Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. Nature 2007; 449:745-7. PubMed